Skip to main content

Advertisement

Log in

Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer

  • CLINICAL TRIAL
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

We evaluated the clinical significance of HER2 in post-chemotherapy specimens after surgery in locally advanced breast cancer (LABC).

Methods

Thirty-four patients with LABC were treated with neoadjuvant chemotherapy, surgery, adjuvant chemotherapy, and radiotherapy. The HER2 status was determined using both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in the paraffin-embedded surgical specimens after neoadjuvant chemotherapy.

Results

The positive rate of HER2 was 41.2% and 32.4% by IHC and FISH, respectively. As the gene copy number of HER2 detected by FISH increased, the staining intensity by IHC increased with positive correlation (adjusted r 2 = 0.743; P < 0.001). According to the cutoff values of IHC score 2+ and 3+ as the positivity criteria, the concordance rates of IHC and FISH were 91.2% (31/34) and 88.2% (30/34), respectively. With the positivity criteria of IHC score ≥2+, the locoregional recurrence-free survival was better in the HER2-negative patients (P = 0.04). Trends were also found for the prolonged distant recurrence-free, disease-free, and overall survivals in the HER2-negative patients by IHC (2+). Trends for poor clinical response (P = 0.06) and more axillary nodes involvement (P = 0.08) were noted in the HER2-positive group by IHC (2+). In post-chemotherapy specimens, the positive HER2 status by IHC staining score ≥ 2+ predicted higher recurrence in LABC.

Conclusion

This suggests that different criteria for the HER2 positivity by IHC can be applied in post-chemotherapy specimens compared with that from pre-chemotherapy biopsies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976

    Article  PubMed  CAS  Google Scholar 

  2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  3. Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, et al (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22:1319–1325

    PubMed  CAS  Google Scholar 

  4. Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, et al (2003) Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer 105:568–573

    Article  PubMed  CAS  Google Scholar 

  5. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648

    PubMed  CAS  Google Scholar 

  6. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651–3664

    PubMed  CAS  Google Scholar 

  7. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ (1999) Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17:1974–1982

    PubMed  CAS  Google Scholar 

  8. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972–1977

    Article  PubMed  CAS  Google Scholar 

  9. Singletary SE, Allred C, Ashley P, Bassett L, Berry D, Bland KI, et al (2002) Breast. In: Greene FL, Balch CM, Page DL, Haller DG, Fleming ID, Morrow M, et al (eds) AJCC Cancer Staging Manual, 6th edn. Springer-Verlag, New York, pp 221–240

    Google Scholar 

  10. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260–1266

    Article  PubMed  CAS  Google Scholar 

  11. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al (2003) Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16:173–182

    Article  PubMed  Google Scholar 

  12. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  13. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in human mammary carcinoma. Science 229:974–976

    Article  PubMed  CAS  Google Scholar 

  14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  15. Pauletti G, Godolphin W, Press MF, Slamon DJ (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63–72

    PubMed  CAS  Google Scholar 

  16. Persons DL, Borelli KA, Hsu PH (1997) Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10:720–727

    PubMed  CAS  Google Scholar 

  17. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, et al (2003) Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-flurouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:1758–1765

    Article  PubMed  CAS  Google Scholar 

  18. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, et al (1994) The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70:335–341

    PubMed  CAS  Google Scholar 

  19. Taucher S, Rudas M, Mader RM, Gnant M, Sporn E, Dubsky P, et al (2003) Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat 82:207–213

    Article  PubMed  CAS  Google Scholar 

  20. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120–1128

    PubMed  CAS  Google Scholar 

  21. Ja Yun Koo, Hy-De Lee, Woo Hee Jung (1998) Overexpression of c-erbB-2 and its relationship with chemotherapy in breast cancer. J Korean Cancer Assoc 30:450–456

    Google Scholar 

  22. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, et al (2004) Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Rad Oncol Biol Phys 59:1337–1342

    Article  CAS  Google Scholar 

  23. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, et al (2002) Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 20:17–23

    Article  PubMed  CAS  Google Scholar 

  24. Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M (1994) C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 47:816–822

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hyun Cheol Chung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moon, Y.W., Jeung, HC., Rha, S.Y. et al. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. Breast Cancer Res Treat 104, 31–37 (2007). https://doi.org/10.1007/s10549-006-9398-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9398-2

Keywords

Navigation